Impact of Obesity on the Bioavailability of Peginterferon-α2a and Ribavirin and Treatment Outcome for Chronic Hepatitis C Genotype 2 or 3

BACKGROUND AND AIMS: Having a body mass index above or equal to 30 kg/m(2) in conjunction with chronic hepatitis C virus infection is associated with non-responsiveness to treatment with interferon and ribavirin, but details regarding the mechanisms whereby obesity reduces the efficacy of therapy re...

Descripción completa

Detalles Bibliográficos
Autores principales: Alsiö, Åsa, Rembeck, Karolina, Askarieh, Galia, Christensen, Peer Brehm, Färkkilä, Martti, Langeland, Nina, Rauning Buhl, Mads, Pedersen, Court, Mørch, Kristine, Haagmans, Bart L., Nasic, Salmir, Westin, Johan, Hellstrand, Kristoffer, Norkrans, Gunnar, Lagging, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3360051/
https://www.ncbi.nlm.nih.gov/pubmed/22655053
http://dx.doi.org/10.1371/journal.pone.0037521

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3360051/
https://www.ncbi.nlm.nih.gov/pubmed/22655053
http://dx.doi.org/10.1371/journal.pone.0037521

Ejemplares similares